Larson Financial Group LLC Increases Stock Position in Stryker Corporation (NYSE:SYK)

Larson Financial Group LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 25.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,934 shares of the medical technology company's stock after acquiring an additional 2,640 shares during the period. Larson Financial Group LLC's holdings in Stryker were worth $4,815,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Elefante Mark B acquired a new stake in Stryker in the fourth quarter valued at $337,000. Mogy Joel R Investment Counsel Inc. lifted its holdings in Stryker by 3.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after acquiring an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. lifted its holdings in Stryker by 1.9% in the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after acquiring an additional 3,341 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in Stryker in the first quarter valued at $1,840,000. Finally, Mar Vista Investment Partners LLC lifted its holdings in Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock valued at $33,572,000 after acquiring an additional 8,353 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Up 0.5%

Shares of Stryker stock opened at $391.46 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19. The business has a fifty day simple moving average of $384.99 and a 200 day simple moving average of $377.37. The stock has a market cap of $149.41 billion, a PE ratio of 52.90, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.50 earnings per share. Research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker's payout ratio is presently 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.20% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on SYK shares. Citigroup reaffirmed a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. BTIG Research set a $403.00 price objective on Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Finally, Roth Mkm lifted their price objective on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $428.55.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.